CA2578630A1 - Pyrimidinylimidazoles as tgf-beta inhibitors - Google Patents
Pyrimidinylimidazoles as tgf-beta inhibitors Download PDFInfo
- Publication number
- CA2578630A1 CA2578630A1 CA002578630A CA2578630A CA2578630A1 CA 2578630 A1 CA2578630 A1 CA 2578630A1 CA 002578630 A CA002578630 A CA 002578630A CA 2578630 A CA2578630 A CA 2578630A CA 2578630 A1 CA2578630 A1 CA 2578630A1
- Authority
- CA
- Canada
- Prior art keywords
- bicyclo
- pyrimidin
- imidazol
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60604504P | 2004-08-31 | 2004-08-31 | |
US60/606,045 | 2004-08-31 | ||
PCT/US2005/030133 WO2006026306A1 (en) | 2004-08-31 | 2005-08-24 | Pyrimidinylimidazoles as tgf-beta inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2578630A1 true CA2578630A1 (en) | 2006-03-09 |
Family
ID=35431931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002578630A Abandoned CA2578630A1 (en) | 2004-08-31 | 2005-08-24 | Pyrimidinylimidazoles as tgf-beta inhibitors |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1786802A1 (ja) |
JP (1) | JP2008511631A (ja) |
AU (1) | AU2005280168A1 (ja) |
CA (1) | CA2578630A1 (ja) |
TW (1) | TW200621753A (ja) |
WO (1) | WO2006026306A1 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008516962A (ja) * | 2004-10-15 | 2008-05-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 血管傷害を治療する方法 |
HUE035575T2 (en) | 2006-10-03 | 2018-05-28 | Genzyme Corp | Use of TGF-beta antagonists to treat children at risk of developing bronchopulmonary dysplasia |
CA2685529A1 (en) | 2007-04-30 | 2008-11-06 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
US8431578B2 (en) * | 2008-01-11 | 2013-04-30 | Novartis Ag | Organic compounds |
US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
EP2660314A4 (en) | 2010-12-27 | 2014-09-03 | Lsip Llc | IPS CELLS AND METHOD FOR THEIR PRODUCTION |
WO2012167261A2 (en) * | 2011-06-03 | 2012-12-06 | Yale University | Compositions and methods for treating and preventing neointimal stenosis |
WO2013014262A1 (en) | 2011-07-27 | 2013-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating myhre syndrome |
MX2014004994A (es) | 2011-10-26 | 2014-08-27 | Seattle Children S Res Inst | Cisteamina en el tratamiento de enfermedad fibrotica. |
WO2014151871A2 (en) | 2013-03-14 | 2014-09-25 | Tolero Pharmaceuticals, Inc. | Jak2 and alk2 inhibitors and methods for their use |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
EP3116512B1 (en) * | 2014-03-11 | 2020-06-10 | Dai Niann-tzyy | Pharmaceutical composition and method for reducing scar formation |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
WO2017100782A1 (en) | 2015-12-11 | 2017-06-15 | Research Institute At Nationwide Children's Hospital | Systems and methods for optimized patent specific tissue engineering vascular grafts |
WO2020023910A1 (en) | 2018-07-26 | 2020-01-30 | Tolero Pharmaceuticals, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
EP3947737A2 (en) | 2019-04-02 | 2022-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR039241A1 (es) * | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
UA80296C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
CN1681805A (zh) * | 2002-09-18 | 2005-10-12 | 辉瑞产品公司 | 作为转化生长因子(tgf)抑制剂的新的咪唑类化合物 |
-
2005
- 2005-08-24 JP JP2007530093A patent/JP2008511631A/ja not_active Withdrawn
- 2005-08-24 EP EP05789340A patent/EP1786802A1/en not_active Withdrawn
- 2005-08-24 AU AU2005280168A patent/AU2005280168A1/en not_active Abandoned
- 2005-08-24 CA CA002578630A patent/CA2578630A1/en not_active Abandoned
- 2005-08-24 WO PCT/US2005/030133 patent/WO2006026306A1/en active Application Filing
- 2005-08-31 TW TW094129857A patent/TW200621753A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2006026306A1 (en) | 2006-03-09 |
TW200621753A (en) | 2006-07-01 |
JP2008511631A (ja) | 2008-04-17 |
EP1786802A1 (en) | 2007-05-23 |
AU2005280168A1 (en) | 2006-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2578630A1 (en) | Pyrimidinylimidazoles as tgf-beta inhibitors | |
AU2003228446B2 (en) | Tri-substituted heteroaryls and methods of making and using the same | |
WO2006026305A1 (en) | Pyrimidinylpyrazoles as tgf-beta inhibitors | |
US10155763B2 (en) | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | |
US20060264440A1 (en) | Pyrazoles and methods of making and using the same | |
AU2003268447B2 (en) | Pyrazolopyridines and method of making and using the same | |
US20100035918A1 (en) | Imidazolone Compounds and Methods of Making and Using the Same | |
US20100105714A1 (en) | Furanone Compounds and Methods of Making and Using The Same | |
US8420685B2 (en) | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |